STUDresearch · Peptide
FGL Peptide
Also known as
FG Loop · NCAM mimetic · FGL peptide
Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.
Peptide
Niche talk
Systemic
Intranasal (human Phase I)
Cognitive / nootropic peptides
Synthetic NCAM-derived FG-loop mimetic studied intranasally in one small Phase I trial; proposed cognitive effects remain mainly preclinical.
What people say
The checked human paper studied synthetic FGLL, an NCAM-derived FG-loop mimetic designed around FGFR signaling. It is not a Khavinson organ bioregulator; human evidence is limited to a small open-label Phase I safety and pharmacokinetic study.
Doses people talk about
Published FGLL cohorts and gray-market FGL claims may not describe identical material, and neither supplies an efficacy progression.
How it may feel
The Phase I study reported only brief intranasal burning or runny eyes in a few participants and did not test cognitive efficacy. Online claims of dramatic memory effects are sparse, unverified, and lack objective testing or durable follow-up.
Published Phase I cohorts25 / 100 / 200 mg intranasal once
Single-dose safety and pharmacokinetic study in 24 healthy men; no cognitive efficacy endpoint.
Unverified forum claimAbout 0.25–0.5 mg intranasal
Sparse self-report with uncertain compound identity, source and objective testing; not comparable to the published FGLL study.
Half-life & effect duration
- Half-life in the body
- Half-lifeNo settled estimate
- Felt duration people report
- One nasal accountStriking memory changes after about 1 week
- Duration after one useNot consistently reported
Cycles people discuss
The published human study used one intranasal dose with eight days of observation. A validated multi-day or repeating human course was not established.
Timing
Plasma was quantifiable up to one hour after 100 mg and four hours after 200 mg in Phase I, but those detection windows do not establish half-life or subjective duration.
Stacks
Nootropic discussions place FGL or FGLL beside Dihexa, Semax, Selank, or Cerebrolysin, but sparse mixed-agent threads do not establish synergy.
Watch for
Phase I acute tolerability: In 24 healthy men given one intranasal dose, brief nasal burning occurred in two participants at 200 mg and brief runny eyes in one at 25 mg; the small open-label study cannot establish long-term safety.
Tap a line to jump into the full notes. Research only — may be wrong.
Timing context & sources
Half-life in the body
The checked human study did not establish a plasma elimination half-life in the accessible report.
FGLL was quantifiable up to one hour after 100 mg and four hours after 200 mg; the 25 mg group was below quantification, but detection duration is not half-life.
Small single-dose open-label study, dose-dependent assay quantification, and potential identity differences between published FGLL and products called FGL online.
- Tolerability, safety and pharmacokinetics of the FGLL peptide, a novel mimetic of neural cell adhesion molecule, following intranasal administration in healthy volunteers (opens in a new tab)Abstract describes an eight-day open-label Phase I study of 24 healthy men given one intranasal 25, 100 or 200 mg dose; it reports brief local events and plasma quantification through one hour at 100 mg and four hours at 200 mg.Small open-label single-dose safety and PK study without a cognitive efficacy endpoint; accessible abstract does not provide an elimination half-life.
Felt duration people report
No dependable felt-duration window was established.
One forum account claimed striking memory changes after about a week at a stated 0.5 mg intranasal amount, while other threads mainly asked for evidence or follow-up and did not supply replication.
Unverified identity and amount, no objective cognitive testing, no baseline or control, possible naming confusion among FGL, FGLL and HA-FGL, and poor follow-up.
- FGL peptide experiences / info (opens in a new tab)Thread includes one user's claims of strong effects and later about 0.5 mg intranasal use with memory changes after a week, plus replies distinguishing FGL, FGLL and HA-FGL and requesting follow-up.Forum page was intermittently slow or unavailable; anonymous claims, uncertain compound identity and amount, no objective testing, no control, and incomplete follow-up.
- FGL peptide experiences (opens in a new tab)Discussion mainly asks for experiences and cautions against assuming a dramatic nootropic effect; it does not provide a robust replicated first-person course.Sparse anonymous discussion with uncertain product identity and little outcome detail.
What people say
- Focus / clarity talk: FGL Peptide shows up in threads about attention, mental fatigue, or “brain fog” days. forum
- Mood adjacency: Some logs mention motivation or anxiety edge changes — highly confounded by caffeine/sleep/stim stacks. anecdote
- Acute vs course: Nasal/SC nootropics often judged same-day; multi-week courses are for “is this real” reassessment. forum
- Preclinical mechanism and efficacy: FG-loop NCAM mimetics were developed around FGFR signaling and synaptic-plasticity or memory hypotheses; these endpoints are primarily preclinical and were not demonstrated as cognitive benefit in the Phase I safety study. animal
- Human evidence boundary: The checked human publication was an eight-day, open-label Phase I study of 24 healthy men and did not establish cognitive efficacy or long-term safety. trial
Doses people talk about
- No settled multi-site human standard. forum
- Published human Phase I: Single intranasal FGLL doses of 25, 100, or 200 mg were studied for short-term safety and pharmacokinetics; this was not an efficacy or self-use protocol. trial
- Route distinction: The checked human Phase I study used intranasal FGLL; parenteral administration appears in preclinical work and isolated community discussion, not an established human subcutaneous regimen. trial
- Framing: NCAM-derived research peptide. animal
How it may feel
- No validated course: The human study used a single intranasal dose. One forum user later described subjective memory changes after about a week at a claimed 0.5 mg intranasal amount, without objective testing or reliable product verification. forum
- Day 1: Most people notice logistics (route, sting, GI) more than a “miracle” effect from FGL Peptide. forum
- Days 2–7: Side-effect window for many agents; benefits, if any, are easy to mis-attribute. forum
- Weeks 1–2: First honest checkpoint in self-logs. forum
- Published acute tolerability: After single intranasal FGLL, two participants at 200 mg reported nasal burning lasting under three minutes and one at 25 mg reported runny eyes lasting under two minutes; later dizziness, vomiting, and headache were judged unrelated by investigators. trial
Cycles people discuss
- Common pattern: Many self-protocols use weeks-on / weeks-off rather than indefinite daily use — cost and caution drive this more than hard science. forum
- No magic cycle: There is rarely one universal “correct” on/off calendar across forums. forum
- Human study exposure: The Phase I publication used a single intranasal dose with eight days of study observation; no validated repeating course was established. trial
- Reassess: Stop and reassess if adverse effects appear; this is not medical care. forum
Timing
- Timing practicalities: People time doses around side effects, training, and sleep more than perfect PK. forum
- Acute window: Nasal/SC nootropics are often judged within hours; true half-life data may be sparse for analogs. forum
- Half-life unresolved: The Phase I abstract reports plasma quantification through one hour after 100 mg and four hours after 200 mg, but these detection windows do not establish an elimination half-life. trial
More on what it is
- Research posture: Educational summary of public discussion and literature themes only. forum
- How people talk about it: Forum volume is a popularity signal for FGL Peptide, not proof it works for you. forum
- What it is: The human Phase I paper studied synthetic FGLL, a neural cell adhesion molecule-derived FG-loop peptide mimetic designed to activate fibroblast growth factor receptor signaling. It is not a Khavinson organ bioregulator. trial
- Evidence honesty: One small open-label Phase I study in 24 healthy men assessed single intranasal doses and short-term safety or pharmacokinetics; proposed memory benefits remain preclinical, and community reports are sparse and unverified. trial
- Research only: Not approved advice for self-experimentation; legality and access vary by place. forum
Stacks
- Nootropic comparison and stack talk: FGL or FGLL is discussed beside agents such as Dihexa, Semax, Selank, or Cerebrolysin, but sparse mixed-agent threads do not establish synergy or a protocol. forum
- Less is clearer: Solo runs make personal n=1 easier to interpret than five-compound blasts. forum
Storage notes
- No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
- Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum
Watch for
- Allergy / unknown impurities: Gray-market risk. forum
- Injection site (if injected): Redness, itch, lumps, bruise — technique and product quality matter. forum
- Unknowns: Long-term safety for gray-market preparations is often poorly characterized. forum
- Stack noise: Sides logged on multi-agent stacks cannot be blamed cleanly on one compound. forum
- Seek care red flags: Severe allergic reaction, chest pain, neuro changes, or uncontrolled BP/glucose need real medical care — not forum advice. forum
- Phase I acute tolerability: In 24 healthy men given one intranasal dose, brief nasal burning occurred in two participants at 200 mg and brief runny eyes in one at 25 mg; the small open-label study cannot establish long-term safety. trial
Evidence mix
Mostly community / anecdote tags
Full: every bullet (trial + community). Use Scan for a faster bro-science read.